Keratinocyte Biomarkers Distinguish Painful Diabetic Peripheral Neuropathy Patients and Correlate With Topical Lidocaine Responsiveness

Overview

Journal Front Pain Res (Lausanne)

Date 2022 Mar 17

PMID 35295428

Authors

Phillip J Albrecht

George Houk

Elizabeth Ruggiero

Marilyn Dockum

Margaret Czerwinski

Joseph Betts

James P Wymer

Charles E Argoff

Frank L Rice

Affiliations

Soon will be listed here.

Abstract

This study investigated quantifiable measures of cutaneous innervation and algesic keratinocyte biomarkers to determine correlations with clinical measures of patient pain perception, with the intent to better discriminate between diabetic patients with painful diabetic peripheral neuropathy (PDPN) compared to patients with low-pain diabetic peripheral neuropathy (lpDPN) or healthy control subjects. A secondary objective was to determine if topical treatment with a 5% lidocaine patch resulted in correlative changes among the quantifiable biomarkers and clinical measures of pain perception, indicative of potential PDPN pain relief. This open-label proof-of-principle clinical research study consisted of a pre-treatment skin biopsy, a 4-week topical 5% lidocaine patch treatment regimen for all patients and controls, and a post-treatment skin biopsy. Clinical measures of pain and functional interference were used to monitor patient symptoms and response for correlation with quantitative skin biopsy biomarkers of innervation (PGP9.5 and CGRP), and epidermal keratinocyte biomarkers (Nav1.6, Nav1.7, CGRP). Importantly, comparable significant losses of epidermal neural innervation (intraepidermal nerve fibers; IENF) and dermal innervation were observed among PDPN and lpDPN patients compared with control subjects, indicating that innervation loss alone may not be the driver of pain in diabetic neuropathy. In pre-treatment biopsies, keratinocyte Nav1.6, Nav1.7, and CGRP immunolabeling were all significantly increased among PDPN patients compared with control subjects. Importantly, no keratinocyte biomarkers were significantly increased among the lpDPN group compared with control. In post-treatment biopsies, the keratinocyte Nav1.6, Nav1.7, and CGRP immunolabeling intensities were no longer different between control, lpDPN, or PDPN cohorts, indicating that lidocaine treatment modified the PDPN-related keratinocyte increases. Analysis of the PDPN responder population demonstrated that increased pretreatment keratinocyte biomarker immunolabeling for Nav1.6, Nav1.7, and CGRP correlated with positive outcomes to topical lidocaine treatment. Epidermal keratinocytes modulate the signaling of IENF, and several analgesic and algesic signaling systems have been identified. These results further implicate epidermal signaling mechanisms as modulators of neuropathic pain conditions, highlight a novel potential mode of action for topical treatments, and demonstrate the utility of comprehensive skin biopsy evaluation to identify novel biomarkers in clinical pain studies.

Citing Articles

Cutaneous targets for topical pain medications in patients with neuropathic pain: individual differential expression of biomarkers supports the need for personalized medicine.

Albrecht P, Liu Y, Houk G, Ruggiero B, Banov D, Dockum M Pain Rep. 2024; 9(2):e1119.

PMID: 38375092 PMC: 10876238. DOI: 10.1097/PR9.0000000000001121.

Cutaneous nerve fiber and peripheral Nav1.7 assessment in a large cohort of patients with postherpetic neuralgia.

Fetell M, Sendel M, Li T, Marinelli L, Vollert J, Ruggerio E Pain. 2023; 164(11):2435-2446.

PMID: 37366590 PMC: 10578423. DOI: 10.1097/j.pain.0000000000002950.

Integrative miRNA-mRNA profiling of human epidermis: unique signature of SCN9A painful neuropathy.

Andelic M, Salvi E, Marcuzzo S, Marchi M, Lombardi R, Cartelli D Brain. 2023; 146(7):3049-3062.

PMID: 36730021 PMC: 10316770. DOI: 10.1093/brain/awad025.

Human-like cutaneous neuropathologies associated with a porcine model of peripheral neuritis: A translational platform for neuropathic pain.

Rice F, Castel D, Ruggiero E, Dockum M, Houk G, Sabbag I Neurobiol Pain. 2019; 5:100021.

PMID: 31194066 PMC: 6550106. DOI: 10.1016/j.ynpai.2018.07.002.

References

North R, Li Y, Ray P, Rhines L, Tatsui C, Rao G . Electrophysiological and transcriptomic correlates of neuropathic pain in human dorsal root ganglion neurons. Brain. 2019; 142(5):1215-1226. PMC: 6487328. DOI: 10.1093/brain/awz063. View

Albrecht P, Hines S, Eisenberg E, Pud D, Finlay D, Connolly K . Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome. Pain. 2006; 120(3):244-266. DOI: 10.1016/j.pain.2005.10.035. View

Albrecht P, Hou Q, Argoff C, Storey J, Wymer J, Rice F . Excessive peptidergic sensory innervation of cutaneous arteriole-venule shunts (AVS) in the palmar glabrous skin of fibromyalgia patients: implications for widespread deep tissue pain and fatigue. Pain Med. 2013; 14(6):895-915. DOI: 10.1111/pme.12139. View

Ko M, Hu M, Hsieh Y, Lan C, Tseng T . Peptidergic intraepidermal nerve fibers in the skin contribute to the neuropathic pain in paclitaxel-induced peripheral neuropathy. Neuropeptides. 2014; 48(3):109-17. DOI: 10.1016/j.npep.2014.02.001. View

Baumbauer K, Deberry J, Adelman P, Miller R, Hachisuka J, Lee K . Keratinocytes can modulate and directly initiate nociceptive responses. Elife. 2015; 4. PMC: 4576133. DOI: 10.7554/eLife.09674. View

Sorensen L, Molyneaux L, Yue D . The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care. 2006; 29(4):883-7. DOI: 10.2337/diacare.29.04.06.dc05-2180. View

Zelman D, Gore M, Dukes E, Tai K, Brandenburg N . Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage. 2005; 29(4):401-10. DOI: 10.1016/j.jpainsymman.2004.06.018. View

Pare M, Albrecht P, Noto C, Bodkin N, Pittenger G, Schreyer D . Differential hypertrophy and atrophy among all types of cutaneous innervation in the glabrous skin of the monkey hand during aging and naturally occurring type 2 diabetes. J Comp Neurol. 2007; 501(4):543-67. DOI: 10.1002/cne.21262. View

Lauria G, Hsieh S, Johansson O, Kennedy W, Leger J, Mellgren S . European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the.... Eur J Neurol. 2010; 17(7):903-12, e44-9. DOI: 10.1111/j.1468-1331.2010.03023.x. View

10.

Sopacua M, Hoeijmakers J, Merkies I, Lauria G, Waxman S, Faber C . Small-fiber neuropathy: Expanding the clinical pain universe. J Peripher Nerv Syst. 2018; 24(1):19-33. DOI: 10.1111/jns.12298. View

11.

Dodick D . CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia. 2019; 39(3):445-458. DOI: 10.1177/0333102418821662. View

12.

Marics B, Peitl B, Varga A, Pazmandi K, Bacsi A, Nemeth J . Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses. Cephalalgia. 2016; 37(6):581-591. DOI: 10.1177/0333102416654883. View

13.

Khodorova A, Navarro B, Jouaville L, Murphy J, Rice F, Mazurkiewicz J . Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med. 2003; 9(8):1055-61. DOI: 10.1038/nm885. View

14.

Shun C, Chang Y, Wu H, Hsieh S, Lin W, Lin Y . Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain. 2004; 127(Pt 7):1593-605. DOI: 10.1093/brain/awh180. View

15.

Ibrahim M, Porreca F, Lai J, Albrecht P, Rice F, Khodorova A . CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A. 2005; 102(8):3093-8. PMC: 549497. DOI: 10.1073/pnas.0409888102. View

16.

Simone D, Nolano M, Johnson T, Wendelschafer-Crabb G, Kennedy W . Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci. 1998; 18(21):8947-59. PMC: 6793545. View

17.

Britland S, Young R, Sharma A, CLARKE B . Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes. 1990; 39(8):898-908. DOI: 10.2337/diab.39.8.898. View

18.

Divisova S, Vlckova E, Srotova I, Kincova S, Skorna M, Dusek L . Intraepidermal nerve-fibre density as a biomarker of the course of neuropathy in patients with Type 2 diabetes mellitus. Diabet Med. 2015; 33(5):650-4. DOI: 10.1111/dme.12890. View

19.

Vincent A, Callaghan B, Smith A, Feldman E . Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011; 7(10):573-83. DOI: 10.1038/nrneurol.2011.137. View

20.

Wilder-Smith E, Ong W, Guo Y, Chow A . Epidermal transient receptor potential vanilloid 1 in idiopathic small nerve fibre disease, diabetic neuropathy and healthy human subjects. Histopathology. 2007; 51(5):674-80. PMC: 2121152. DOI: 10.1111/j.1365-2559.2007.02851.x. View